Improvement of the Patientenadherence and avoidance of side effects by one special speech hour for oral tumour therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00010797

Enrollment

100

Registered

2016-07-14

Start date

2016-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PATIENTENADHERENCE QUALITY OF LIFE CURVES TOXICITYCURVE NCI CTC Version 4.0 HOSPITALISATIONS DOCTOR'S CONTACTS C18 C19 C20 C50 C34 C64 C43 C83.1 C91.1 C82 C90.0 D47.4 D45 C92.1

Interventions

Group 1: Here , the doctor determines the examination intervals between the oral anti-proliferative therapy . Group 2: In addition to the medical contacts find weekly contacts by a specialized technic

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: inclusion criteria All patients in whom a secured hematologic or oncologic disease following entity exists and which are treated with an oral anti-proliferative therapy : Colorektaleskarzinom breast cancer Non small cell lung cancer ( adenocarcinoma ) Renal Cell Carcinoma Malignant melanoma Mantle cell lymphoma Chronic Lymphocytic Leukemia follicular lymphoma multiple myeloma Primary myelofibrosis polycythemia vera Chronic myeloid leukemia Written informed consent Age = 18 years Ability to work independently tablets An adequate knowledge Legal capacity Estimated life expectancy = 3 months ECOG performance status 0-2

Exclusion criteria

Exclusion criteria: Lack of ability to independently tablets Lack of knowledge of German or lack of ability to autonomously understand and fill out the applications described in the study questionnaires Missing or limited legal capacity Participation in another clinical trial with not yet approved substances Any significant concomitant disease that excludes the participation of the patient in the study of the investigator 's opinion

Design outcomes

Primary

Measure	Time frame
Primary study endpoints The following parameters are compared for differences in membership of the cohorts ( routine medical check vs. co-supervision by a specialist for oral and subcutaneous tumor therapy ) : adherence all 3 months Query on adherence questionnaire Independent verification of the drugs taken on the basis of brought Blister (study - nurses ) patient safety all 3 months Detection of adverse reactions by CTCAE v4.03 criteria patient satisfaction Query by standardized questionnaire time Duration of examination / training talks Waiting times for consultation	—

Measure

Time frame

Primary study endpoints The following parameters are compared for differences in membership of the cohorts ( routine medical check vs. co-supervision by a specialist for oral and subcutaneous tumor therapy ) : adherence all 3 months Query on adherence questionnaire Independent verification of the drugs taken on the basis of brought Blister (study - nurses ) patient safety all 3 months Detection of adverse reactions by CTCAE v4.03 criteria patient satisfaction Query by standardized questionnaire time Duration of examination / training talks Waiting times for consultation

—

Secondary

Measure	Time frame
Patient adherence Patient satisfaction Patient safety	—

Countries

Germany

Contacts

Public ContactUrsula Vehling-Kaiser

Onkologisch-Palliativmedizinisches Netzwerk

info@vehling-kaiser.de0871/97403433

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026